Corline Biomedical
9.86
SEK
-2.86 %
Less than 1K followers
CLBIO
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
Corline Biomedical is active in the pharmaceutical industry. The company works with the substance heparin and has developed a portfolio of drug candidates for use in connection with organ and cell transplantation. The company sells its proprietary product CHS™ to medical technology customers, and is developing Renaparin® for use in regenerative medicine and organ transplantation. The headquarters are located in Uppsala.
Read moreMarket cap
241.48M SEK
Turnover
194.47K SEK
Revenue
9.78M
EBIT %
-236.91 %
P/E
-
Dividend yield-%
-
Financial calendar
26/8
2025
Interim report Q2'25
11/11
2025
Interim report Q3'25
17/2
2026
Annual report '25
All
Press releases
3rd party
ShowingAll content types
Analyst Group: Analyst Group intervjuar Corline Biomedicals VD Henrik Nittmar
Redeye: Corline Biomedical Q1 - Exciting quarters ahead
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools